Massachusetts’ biotech workforce and funding picture has shifted as the state appears to be rebounding from earlier headwinds. MassBio’s Industry Snapshot reports the Massachusetts biopharma workforce shrank by about 3,600 employees in 2025, but venture capital in the first half of 2026 totaled $3.45 billion—up 25% year over year—alongside eight IPOs, the highest level since 2021. The report flags ongoing pressure on early-stage investment: seed round counts rose to 21 in the first half of 2026, but average seed sizes fell to $4.6 million from $7.6 million. It also notes that NIH dollars per capita remain strong while overall NIH awards fell 6.2%, suggesting potential federal priority shifts. For regional strategists and investors, the mix—strong exits and public listings but softer early funding—points to uneven risk capital distribution inside the state’s “biotech flywheel.”